In United Therapeutics Corp. v. Sandoz, Inc., Judge Peter G. Sheridan of the District of New Jersey ruled that Sandoz’s proposed label for a generic version of UTC’s anti-hypertensive Remodulin (treprostinil sodium) injection did not induce infringement of various UTC method patent claims.  (Civil Action No. 3:13-cv-1617-PGS-LHG, Dkt. No. 364).  As a way to reduce […]